ClinicalTrials.gg
RecruitingNCT07465783DOUCE NUIT IMTUpdated Aug 3, 2026

Effects of Musical Intervention by a Therapist (IMT) on Falling Asleep and Behavioral Regulation in a Secure Care Unit (SCU)

An interventional study of Test musicale intervention and Controle: audio book in Alzheimer Disease or Associated Disorder, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 1 site in France. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Saint Etienne — 3 open to participants now, 3 under way, none of them phase 3. Alzheimer Disease · Centre Hospitalier Universitaire de Saint Etienne.

Started
2026
with 2 others
No phase
8 of 11
2 open now
Registered
10th of 11
by date

Among the 11 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Saint Etienne, this one is one of 3 that started in 2026, is one of 8 with no phase, and was the 10th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 11 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Saint Etienne are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Saint Etienne, or all of them as a file.
02

Study summary

This is a prospective, multicenter study designed to evaluate the benefits of an evening music-based intervention on sundowning syndrome in patients with Alzheimer's disease or related disorders in a Protect lLife Unit setting.

Read the detailed description

This study will employ a randomized, cluster-organized, crossover design to compare the effects of a music-based intervention (TEST) with an audiobook listening intervention (CONTROL). Both interventions will be delivered by a therapist in the participants' living environment over ten evening sessions per intervention period. Each participant will serve as their own control and will be exposed to both intervention conditions. The sequence of intervention periods ("TEST followed by CONTROL" or "CONTROL followed by TEST") will be randomized at the cluster level within participating protected care units (UVP). Behavioral and actigraphic outcomes will be collected and analyzed at baseline, during, and after each intervention period.

03

Conditions studied

  • Alzheimer Disease or Associated Disorder

Keywords

  • Alzheimer's disease
  • Behavior disorder
  • Music intervention
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signature of consent by the patient's legal guardian obtained after providing information
  • Patients aged 60 and over who meet the diagnostic criteria for Alzheimer's disease and related disorders, including mainly: Lewy body disease, frontotemporal lobar degeneration, progressive supranuclear palsy, corticobasal degeneration, vascular encephalopathy, alcoholic dementia, primary progressive aphasia syndrome, posterior cortical atrophy syndrome (France Alzheimer, 2024).
  • Patient living in a secure care unit
  • If taking psychotropic drugs, they must have been stable for 3 months
  • If taking level 2 or 3 painkillers, they must have been stable for 1 month

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • Participation in a study on a drug/medical device/treatment technique that may affect sleep or behavior.
  • Highly sedated patients,
  • Patients with acute medical instability,
  • Patients with productive delusions,
  • Patients who have been in the unit for less than 1 month
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Test musicale intervention

    musicale intervention before night

    Other: Test musicale intervention

  • Active comparator
    Controle: audio book

    listenning audio book with an experimenter

    Other: Controle: audio book

Interventions

  • OtherTest musicale intervention

    listenning music

  • OtherControle: audio book

    listenning audio books

06

What researchers measure

Primary outcomes

  1. Music

    Changing in sleep duration, following an evening music-based intervention in older adults with Alzheimer's disease or related disorders living in a protected care unit (UVP), assessed by actigraphy

    Time frame: Baseline (Days 1-10); TEST intervention (Days 11-20); post-intervention follow-up (Days 21-40); CONTROL intervention (Days 41-50); post-control follow-up (Days 51-60). Outcomes assessed throughout all study periods.

Secondary outcomes

  1. sleep parameter (1)

    Change in sleep onset latency , assessed by actigraphy.

    Time frame: hroughout all study periods (Days 1-60, including baseline, TEST intervention, post-TEST follow-up, CONTROL intervention, post-CONTROL follow-up)

  2. Daytime disruptive behaviors

    Change in disruptive behaviors assessed using the Cohen-Mansfield Agitation Inventory (CMAI), a categorical agitation scale, (score 0 to 29, Low score : low or infrequent agitation ; High score : frequent or intense agitation

    Time frame: Throughout all study periods (Days 1-60).

  3. Falls

    Change in the number of falls recorded during each study period.

    Time frame: Throughout all study periods (Days 1-60)

  4. sleep parameter (2)

    number of nocturnal awakenings, assessed by actigraphy.

    Time frame: Throughout all study periods (Days 1-60, including baseline, TEST intervention, post-TEST follow-up, CONTROL intervention, post-CONTROL follow-up)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jul 2027, 17 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 17 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Mar 12, 2026
StartActual
Feb 2, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Sep 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07465783
Collaborators
Lyon Neuroscience Research Center (CRNL)
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Feb 2, 2026
Primary completion
Jul 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Aug 3, 2026

Study contacts

Isabelle ROUCH, MD
Contact
isabelle.rouch@chu-st-etienne.fr
(0)477127399 ext. +33
Céline BORG, PhD
Contact
celine.borg@chu-st-etienne.fr
(0)477127805 ext. +33
Isabelle ROUCH, MD
principal investigator · CHU de Saint-Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion